Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey
Crossref DOI link: https://doi.org/10.1007/s40290-017-0203-9
Published Online: 2017-08-28
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Davis, Kimberly H.
Asiimwe, Alex
Zografos, Laurie J.
McSorley, David J.
Andrews, Elizabeth B.
Funding for this research was provided by:
Bayer AG
License valid from 2017-08-28